Compare UPBD & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | ALVO |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1996 | N/A |
| Metric | UPBD | ALVO |
|---|---|---|
| Price | $19.92 | $3.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $32.25 | $8.00 |
| AVG Volume (30 Days) | ★ 726.9K | 401.1K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $4,695,061,000.00 | N/A |
| Revenue This Year | $5.96 | $13.28 |
| Revenue Next Year | $6.47 | $18.63 |
| P/E Ratio | ★ $15.80 | $18.20 |
| Revenue Growth | ★ 8.67 | N/A |
| 52 Week Low | $15.82 | $3.03 |
| 52 Week High | $28.03 | $11.85 |
| Indicator | UPBD | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.58 | 44.66 |
| Support Level | $17.05 | $3.03 |
| Resistance Level | $20.28 | $3.93 |
| Average True Range (ATR) | 0.75 | 0.20 |
| MACD | 0.25 | 0.03 |
| Stochastic Oscillator | 69.96 | 26.27 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.